Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth B Gordon

Showing results (21-30 of 136) with videos related to

Pageof 14
Sort By:
Expert Review of Clinical Immunology|May 19, 2010
The new psoriasis pathway: toward a unified theory of immunopathogenesisStephanie L Melhis, Kenneth B Gordon
Immunotherapy|November 14, 2022
Deucravacitinib in moderate-to-severe psoriasisAlan Vu, Victoria Maloney, Kenneth B Gordon
Seminars in Cutaneous Medicine and Surgery|May 1, 2010
Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasisMona Gandhi, Eihab Alwawi, Kenneth B Gordon
Immunotherapy|October 4, 2019
Risankizumab in moderate-to-severe plaque psoriasisLinda Serrano, Victoria Maloney, Kenneth B Gordon
Expert Opinion on Biological Therapy|October 15, 2022
Anti-IL 23 biologics for the treatment of plaque psoriasisAlan Vu, Caden Ulschmid, Kenneth B Gordon
Archives of Dermatology|May 22, 2002
Biologic therapy for psoriasis: the new therapeutic frontierPrashant Singri, Dennis P West, Kenneth B Gordon
American Journal of Clinical Dermatology|July 13, 2024
Sequencing of Targeted Therapy in Psoriasis: Does it Matter?Nicole D Boswell, Shikha Singla, Kenneth B Gordon
Drug Safety|October 17, 2002
Comparative tolerability of systemic treatments for plaque-type psoriasisStacy L McClure, Jayme Valentine, Kenneth B Gordon
Dermatologic Therapy|October 23, 2009
Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?Eihab A Alwawi, Eliana Krulig, Kenneth B Gordon
Journal of the American Academy of Dermatology|March 19, 2017
Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fracturesParul Kathuria, Kenneth B Gordon, Jonathan I Silverberg
Pageof 14

Showing results (21-30 of 136) with videos related to

Sort By:
Pageof 14
Expert Review of Clinical Immunology|May 19, 2010
The new psoriasis pathway: toward a unified theory of immunopathogenesisStephanie L Melhis, Kenneth B Gordon
Immunotherapy|November 14, 2022
Deucravacitinib in moderate-to-severe psoriasisAlan Vu, Victoria Maloney, Kenneth B Gordon
Seminars in Cutaneous Medicine and Surgery|May 1, 2010
Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasisMona Gandhi, Eihab Alwawi, Kenneth B Gordon
Immunotherapy|October 4, 2019
Risankizumab in moderate-to-severe plaque psoriasisLinda Serrano, Victoria Maloney, Kenneth B Gordon
Expert Opinion on Biological Therapy|October 15, 2022
Anti-IL 23 biologics for the treatment of plaque psoriasisAlan Vu, Caden Ulschmid, Kenneth B Gordon
Archives of Dermatology|May 22, 2002
Biologic therapy for psoriasis: the new therapeutic frontierPrashant Singri, Dennis P West, Kenneth B Gordon
American Journal of Clinical Dermatology|July 13, 2024
Sequencing of Targeted Therapy in Psoriasis: Does it Matter?Nicole D Boswell, Shikha Singla, Kenneth B Gordon
Drug Safety|October 17, 2002
Comparative tolerability of systemic treatments for plaque-type psoriasisStacy L McClure, Jayme Valentine, Kenneth B Gordon
Dermatologic Therapy|October 23, 2009
Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?Eihab A Alwawi, Eliana Krulig, Kenneth B Gordon
Journal of the American Academy of Dermatology|March 19, 2017
Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fracturesParul Kathuria, Kenneth B Gordon, Jonathan I Silverberg
Pageof 14